Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 7/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 4/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 2/20 | 0.38 |
| ▸ | FLT4 | P35916 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22925921 | 1.00 | VCP (0.46) | VCPTRPV1KDRALOX5CYP1A2 | |
| SCHEMBL29620883 | 0.86 | KDR (0.47) | VCPTRPV1KDRALOX5FLT1 | |
| SCHEMBL22925920 | 0.86 | KDR (0.47) | VCPTRPV1KDRALOX5FLT1 | |
| SCHEMBL22925673 | 0.84 | TRPV1 (0.59) | VCPTRPV1KDRALOX5FLT1 | |
| SCHEMBL22925909 | 0.82 | ACHE (0.47) | KDRFLT1 | |
| SCHEMBL29696325 | 0.82 | ACHE (0.47) | KDRFLT1 | |
| SCHEMBL28939252 | 0.80 | KDR (0.42) | TRPV1KDRCYP1A2FLT1FLT4 | |
| SCHEMBL29620994 | 0.79 | KDR (0.37) | VCPTRPV1KDRALOX5CYP1A2 | |
| SCHEMBL28733789 | 0.78 | KDR (0.36) | VCPTRPV1KDRALOX5CYP1A2 | |
| SCHEMBL22925922 | 0.77 | KDR (0.36) | VCPTRPV1KDRALOX5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448371-B2 | Inhibitor compounds | Cincera Therapeutics Pty Ltd (AU) | 2025-10-21 | — | — | US | claimed |
| CN-114450281-B | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2024-08-16 | — | — | CN | claimed |
| CN-114450281-B | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2024-08-16 | — | — | CN | disclosed |
| EP-4003986-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450281-A | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2022-05-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448371-B2 | Inhibitor compounds | SERPINB1, MMP1, SSB | VCP 595/4885TRPV1 4690/4885KDR 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.